September 25, 2016 8:19 AM ET

Biotechnology

Company Overview of Apellis Pharmaceuticals, Inc.

Company Overview

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

6400 Westwind Way

Suite A

Crestwood, KY 40014

United States

Founded in 2009

11 Employees

Phone:

502-241-4114

Fax:

502-241-4116

Key Executives for Apellis Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 44
Co-Founder and Chief Operating Officer
Age: 46
Co-Founder and Vice-President of Clinical Development
Age: 42
Co-Founder, Director, Chairman of Audit Committee and Member of Compensation Committee
Age: 43
Interim Chief Financial Officer
Age: 59
Compensation as of Fiscal Year 2016.

Apellis Pharmaceuticals, Inc. Key Developments

Apellis Pharmaceuticals, Inc. Appoints Robert Kim as its Chief Medical Officer

Apellis Pharmaceuticals, Inc. announced the expansion of its executive team with the addition of Dr. Robert Kim as its Chief Medical Officer. Dr. Kim will help the company optimize its drug development strategy as its clinical programs progress toward late stage clinical testing. Dr. Kim has over 30 years of clinical experience in ophthalmology.

Apellis Announces Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor

Apellis Pharmaceuticals, Inc. announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2. The trials were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous injection in healthy adult volunteers. Forty subjects were administered APL-2 subcutaneously (SC) either as a single dose (ranging from 45 to 1,440mg) or repeated doses for 28 consecutive days (ranging from 30 to 270 mg/day). Both studies concluded that pharmacological doses of APL-2 were safe and well tolerated and that APL-2's PK /PD profile supports daily SC administration. In addition, complement-mediated hemolysis (destruction of the red blood cells) was assessed and daily APL-2 doses of 180mg and 270mg significantly reduced hemolytic activity as early as eight days after the start of dosing, and this inhibition was maintained throughout the dosing period. In parallel, Apellis has also initiated two Phase 1b clinical trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) designed to assess the safety, preliminary efficacy and pharmacokinetics of subcutaneously administered APL-2 alone or in combination with eculizumab. Data are expected to be presented at the American Society of Hematology (ASH) annual meeting in December 2016.

Apellis Pharmaceuticals, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:05 AM

Apellis Pharmaceuticals, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:05 AM. Venue: The Waldorf Astoria, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 24, 2015
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Apellis Pharmaceuticals, Inc., please visit www.apellis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.